Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 68 |
| Active Pipeline (Recruiting Now) | 37 (33) |
| Completed vs Stopped Early | 14 / 16 (23.5%) |
| Median Closed Actual Enrollment | 25 participants |
| Physical Hospital Site Disclosure | 99.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | 59 |
| Emory Winship Cancer Institute | Atlanta, GA | 4 |
| Cleveland Clinic | Cleveland, OH | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04045665 | Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase III | RECRUITING |
| NCT05835466 | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Mount Sinai Health System across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Icahn School of Medicine at Mount Sinai Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.